GNLX · GENELUX Corp
$2.44
-0.08 (-3.17%)
At close · Sep 4
Going-concern doubt
— flagged Aug 13, 2026
Substantial doubt about the company's ability to continue as a going concern.
“The accompanying condensed financial statements have been prepared on a going concern basis, which contemplates the realization of assets and the settlement of liabilities and commitments in the normal course of business. The Company has experienced recurring losses from operations since inception and incurred a net loss of $18.4 million and cash used in operations of $12.5 million during the six months ended June 30, 2026. These factors raise substantial doubt about the Company's ability to continue as a going concern.”View the 10-Q filed Aug 13, 2026
Market Cap
$110.40M
Shares
45.25M
Named-executive compensation from the company's DEF 14A proxy statements — salary, bonus, stock and option awards, non-equity incentive, and the company-reported total per executive per fiscal year, exactly as disclosed in the Summary Compensation Table.
Fiscal 2025
| Executive | Role | Total |
|---|---|---|
| Thomas D. Zindrick | President and Chief Executive Officer | $4,277,083 |
| Matthew Pulisic | Chief Financial Officer | $1,487,011 |
| Joseph Cappello | Chief Technical Officer | $1,442,092 |
Fiscal 2024
| Executive | Role | Total |
|---|---|---|
| Joseph Cappello | Chief Technical Officer | $648,074 |
| Thomas D. Zindrick | President and Chief Executive Officer | $1,578 |
| Matthew Pulisic | Chief Financial Officer | — |
Executive changes
| Person | Role | Change | Filed |
|---|---|---|---|
| Jason Litten, M.D. | Chief Medical Officer | Appointed | 2026-01-02 |
| Paul Scigalla, M.D. | Chief Medical Officer | Resigned | 2026-01-02 |
Key facts
CIK
1231457
CUSIP
36870H103
13F (30d)
35 filings
35 filers
Visit website
Investor relations